With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of Denmark after cashing in on the weight-loss drug boom. The Novo Nordisk ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

Danish pharmaceutical company Novo Nordisk has launched its mega-popular weight loss drug Wegovy in China — and it's charging just a tiny fraction of what the blockbuster drug costs in the US.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other profitable European stocks. After the U.S. Presidential elections, the global economies ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other most promising healthcare stocks according to hedge funds. The healthcare sector depends on ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...